Fluvastatin Sodium Structural Formula (Image 1)
Fluvastatin Sodium Tablet, Film Coated, Extended Release
Product Images NDC 0093-7446
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Fluvastatin Sodium (NDC 0093-7446). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Primary Endpoint – Recurrent Cardiac Events (cardiac Death, Nonfatal Mi Or Revascularization Procedure) (itt Population) (Image 2)
This is a statistical report of patients' survival rates. It shows the percentage of patients without events, which implies the percentage of patients who survived without any adverse conditions. It also provides related statistics such as Cox P-value, Log-Rank P-value, and Hazard Rt, along with the patients at risk based on the year of randomization. The text mentions several numeric values, representing the percentage of patients surviving after a particular year since randomization. It is not clear what type of events or patients the report refers to.*
Figure 2: Fluvastatin Capsules Intervention Prevention Study (Primary and Secondary Endpoints)
This appears to be a results table of a clinical trial comparing a medication called Fivastat capsules to a placebo for the prevention of cardiac events. The table lists various endpoints such as cardiac death, non-fatal myocardial infarction, and revascularization both as a primary endpoint and as secondary endpoints. Risk reduction and Cox Risk Ratio are also mentioned. However, the output is missing some critical information and has unclear formatting, making it difficult to interpret the results.*
Figure 3: Change In Minimum Lumen Diameter (mm) (Image 4)
This document reports the change in minimum lumen diameter for patients taking Fluvastatin capsules versus Placebo capsules in both monotherapy and combination therapy. The results show a significant difference in minimum lumen diameter when comparing Fluvastatin capsules versus Placebo capsules. However, some parts of the text are not readable.*
Figure 4: Change In % Diameter Stenosis (Image 5)
80 mg, 30 Tablets Label (Image 6)
Description not available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
